On Monday, when the FDA came out against Sarepta Therapeutics’ (SRPT) Duchenne muscular dystrophy drug Vyondys 53, investors knew the shockwaves would immediately …
It’s a big day for Sarepta Therapeutics (NASDAQ:SRPT) investors. The company released positive preliminary results from a gene therapy for Duchenne muscular dystrophy (DMD) …
Wave Life Sciences (NASDAQ:WVE) shares tumble nearly 14% in Tuesday’s trading session, following the news that competitor Sarepta (NASDAQ:SRPT) achieved impressive results in a Phase 1/2a gene therapy …
Can you feel the ground moving beneath your feet? Shares of Sarepta (NASDAQ:SRPT) skyrocketed nearly 60% this morning, following the announcement of positive …
Is SRPT a bull’s dream? Oppenheimer’s Hartaj Singh believes with commercial and clinical momentum into the new year, and no real DMD rivals for 3 to 5 years, the drug maker is a good bet.
Cantor: CELG pipeline needs commercial juice; Cowen: Sarepta soars on strong Exondys 51 orphan launch.
In a research note published today, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (SRPT) with a $34 price target, following the appointment of John Hodgman, …
